Free Trial
NASDAQ:ZBIO

Zenas BioPharma Q4 2025 Earnings Report

Zenas BioPharma logo
$20.83 +0.07 (+0.34%)
Closing price 04:00 PM Eastern
Extended Trading
$21.20 +0.38 (+1.80%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zenas BioPharma EPS Results

Actual EPS
-$4.54
Consensus EPS
-$1.22
Beat/Miss
Missed by -$3.32
One Year Ago EPS
N/A

Zenas BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$28.75 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zenas BioPharma Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Zenas BioPharma's Q1 2026 earnings is estimated for Thursday, May 14, 2026, based on past reporting schedules, with a conference call scheduled on Friday, May 15, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Zenas BioPharma Earnings Headlines

Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
See More Zenas BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email.

About Zenas BioPharma

Zenas BioPharma (NASDAQ:ZBIO) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies. Its integrated research infrastructure encompasses medicinal chemistry, in vitro and in vivo pharmacology, as well as manufacturing capabilities to support rapid progression of lead molecules into clinical development.

The company’s pipeline includes immuno-oncology candidates designed to modulate checkpoint pathways in solid tumors, alongside antiviral programs targeting broad-spectrum viral threats. Each program is engineered to combine high specificity with favorable pharmacokinetic properties, with key assets currently in IND-enabling stages and early clinical trials.

To advance its programs, Zenas BioPharma collaborates with academic institutions and contract research organizations, leveraging external expertise and resources. Serving global markets, the company is committed to addressing unmet medical needs and bringing differentiated therapies to patients worldwide.

View Zenas BioPharma Profile